Finastéride oral 1 mg face à Finastéride topique 0,25 %

At week 24, the adjusted mean change from baseline in TAHC was significantly greater with topical finasteride than with pla- cebo(20.2vs.6.7hairs;P < 0.001),andwasnumericallysimilar to that with oral finasteride (21.1 hairs;

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

At week 24, the adjusted mean change from baseline in TAHC was significantly greater with topical finasteride than with pla- cebo(20.2vs.6.7hairs;P < 0.001),andwasnumericallysimilar to that with oral finasteride (21.1 hairs;

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2 Changes from baseline in secondary efficacy variables (ITTpopulation) Variable Topicalfinasteride Placebo Oralfinasteride (N=105) (N=97) (N=48) Hairwidth,lm[adjustedmean(SE)] Week24 (cid:1)0.81(0.35) (cid:1)1.53(0.37) 0.72(0.47)

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2 Changes from baseline in secondary efficacy variables (ITTpopulation) Variable Topicalfinasteride Placebo Oralfinasteride (N=105) (N=97) (N=48) Hairwidth,lm[adjustedmean(SE)] Week24 (cid:1)0.81(0.35) (cid:1)1.53(0.37) 0.72(0.47)

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table3 Percentage of responders for secondary endpoints at from week24:posthocsensitivityanalysis(safetypopulation) https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, Respondersa Topical Placebo Oral P-value finasteride (N=181) finasteride (topical (N=181) (N=84) finasteride vs.placebo) Investigator 42.0 27.6 35.7 <0.005 assessment(%) Blinded-assessor 26.0 16.0 28.6 0.02 assessment(%) MHGQ–patientassessment(%) Smallerbaldspot 29.3 21.0 31.0 0.069 Hairappearance 40.9 28.7 36.9 0.015 Wiley Hairgrowth 39.8 32.0 31.0 0.12 Slowdown 41.4 31.5 40.5 <0.05 Online hairloss Library Satisfaction–front 21.6 11.1 17.9 0.007 hairline on Satisfaction–head 26.0 19.3 23.8 0.13 [03/11/2022]. top Overallchange 26.5 19.9 25.0 0.13

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table3 Percentage of responders for secondary endpoints at from week24:posthocsensitivityanalysis(safetypopulation) https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, Respondersa Topical Placebo Oral P-value finasteride (N=181) finasteride (topical (N=181) (N=84) finasteride vs.placebo) Investigator 42.0 27.6 35.7 <0.005 assessment(%) Blinded-assessor 26.0 16.0 28.6 0.02 assessment(%) MHGQ–patientassessment(%) Smallerbaldspot 29.3 21.0 31.0 0.069 Hairappearance 40.9 28.7 36.9 0.015 Wiley Hairgrowth 39.8 32.0 31.0 0.12 Slowdown 41.4 31.5 40.5 <0.05 Online hairloss Library Satisfaction–front 21.6 11.1 17.9 0.007 hairline on Satisfaction–head 26.0 19.3 23.8 0.13 [03/11/2022]. top Overallchange 26.5 19.9 25.0 0.13

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table3 Percentage of responders for secondary endpoints at from week24:posthocsensitivityanalysis(safetypopulation) https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, Respondersa Topical Placebo Oral P-value finasteride (N=181) finasteride (topical (N=181) (N=84) finasteride vs.placebo) Investigator 42.0 27.6 35.7 <0.005 assessment(%) Blinded-assessor 26.0 16.0 28.6 0.02 assessment(%) MHGQ–patientassessment(%) Smallerbaldspot 29.3 21.0 31.0 0.069 Hairappearance 40.9 28.7 36.9 0.015 Wiley Hairgrowth 39.8 32.0 31.0 0.12 Slowdown 41.4 31.5 40.5 <0.05 Online hairloss Library Satisfaction–front 21.6 11.1 17.9 0.007 hairline on Satisfaction–head 26.0 19.3 23.8 0.13 [03/11/2022]. top Overallchange 26.5 19.9 25.0 0.13

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table3 Percentage of responders for secondary endpoints at from week24:posthocsensitivityanalysis(safetypopulation) https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, Respondersa Topical Placebo Oral P-value finasteride (N=181) finasteride (topical (N=181) (N=84) finasteride vs.placebo) Investigator 42.0 27.6 35.7 <0.005 assessment(%) Blinded-assessor 26.0 16.0 28.6 0.02 assessment(%) MHGQ–patientassessment(%) Smallerbaldspot 29.3 21.0 31.0 0.069 Hairappearance 40.9 28.7 36.9 0.015 Wiley Hairgrowth 39.8 32.0 31.0 0.12 Slowdown 41.4 31.5 40.5 <0.05 Online hairloss Library Satisfaction–front 21.6 11.1 17.9 0.007 hairline on Satisfaction–head 26.0 19.3 23.8 0.13 [03/11/2022]. top Overallchange 26.5 19.9 25.0 0.13

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table3 Percentage of responders for secondary endpoints at from week24:posthocsensitivityanalysis(safetypopulation) https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, Respondersa Topical Placebo Oral P-value finasteride (N=181) finasteride (topical (N=181) (N=84) finasteride vs.placebo) Investigator 42.0 27.6 35.7 <0.005 assessment(%) Blinded-assessor 26.0 16.0 28.6 0.02 assessment(%) MHGQ–patientassessment(%) Smallerbaldspot 29.3 21.0 31.0 0.069 Hairappearance 40.9 28.7 36.9 0.015 Wiley Hairgrowth 39.8 32.0 31.0 0.12 Slowdown 41.4 31.5 40.5 <0.05 Online hairloss Library Satisfaction–front 21.6 11.1 17.9 0.007 hairline on Satisfaction–head 26.0 19.3 23.8 0.13 [03/11/2022]. top Overallchange 26.5 19.9 25.0 0.13

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table3 Percentage of responders for secondary endpoints at from week24:posthocsensitivityanalysis(safetypopulation) https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, Respondersa Topical Placebo Oral P-value finasteride (N=181) finasteride (topical (N=181) (N=84) finasteride vs.placebo) Investigator 42.0 27.6 35.7 <0.005 assessment(%) Blinded-assessor 26.0 16.0 28.6 0.02 assessment(%) MHGQ–patientassessment(%) Smallerbaldspot 29.3 21.0 31.0 0.069 Hairappearance 40.9 28.7 36.9 0.015 Wiley Hairgrowth 39.8 32.0 31.0 0.12 Slowdown 41.4 31.5 40.5 <0.05 Online hairloss Library Satisfaction–front 21.6 11.1 17.9 0.007 hairline on Satisfaction–head 26.0 19.3 23.8 0.13 [03/11/2022]. top Overallchange 26.5 19.9 25.0 0.13

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2 Changes from baseline in secondary efficacy variables (ITTpopulation) Variable Topicalfinasteride Placebo Oralfinasteride (N=105) (N=97) (N=48) Hairwidth,lm[adjustedmean(SE)] Week24 (cid:1)0.81(0.35) (cid:1)1.53(0.37) 0.72(0.47) Self-administeredMHGQoverallscore†[adjustedmean(SE)] Week24 2.8(0.75) 3.0(0.95) 2.9(0.89) Investigator-assessedchangeinpatienthairgrowth/loss‡[adjustedmean (SE)] Week24 0.8(0.09)* 0.3(0.09) 0.7(0.12)

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2 Changes from baseline in secondary efficacy variables (ITTpopulation) Variable Topicalfinasteride Placebo Oralfinasteride (N=105) (N=97) (N=48) Hairwidth,lm[adjustedmean(SE)] Week24 (cid:1)0.81(0.35) (cid:1)1.53(0.37) 0.72(0.47) Self-administeredMHGQoverallscore†[adjustedmean(SE)] Week24 2.8(0.75) 3.0(0.95) 2.9(0.89) Investigator-assessedchangeinpatienthairgrowth/loss‡[adjustedmean (SE)] Week24 0.8(0.09)* 0.3(0.09) 0.7(0.12)

Citation complémentaire (significativite)

assessed adjusted mean change from baseline to week 24 in OA patient hair growth/loss at the vertex was statistically signifi- articles cantly greater with topical finasteride than placebo (0.8 vs. 0.3, are P < 0.001) and was numerically similar to that with oral finas- governed teride(0.7). Blinded-assessor evaluation ofpatient hairgrowth/

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2 Changes from baseline in secondary efficacy variables (ITTpopulation) Variable Topicalfinasteride Placebo Oralfinasteride (N=105) (N=97) (N=48) Hairwidth,lm[adjustedmean(SE)] Week24 (cid:1)0.81(0.35) (cid:1)1.53(0.37) 0.72(0.47) Self-administeredMHGQoverallscore†[adjustedmean(SE)] Week24 2.8(0.75) 3.0(0.95) 2.9(0.89) Investigator-assessedchangeinpatienthairgrowth/loss‡[adjustedmean (SE)] Week24 0.8(0.09)* 0.3(0.09) 0.7(0.12) Blinded-assessorchangeinpatienthairgrowth/loss‡[adjustedmean (SE)] Week24 0.2(0.09) 0.1(0.09) 0.3(0.12)

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2 Changes from baseline in secondary efficacy variables (ITTpopulation) Variable Topicalfinasteride Placebo Oralfinasteride (N=105) (N=97) (N=48) Hairwidth,lm[adjustedmean(SE)] Week24 (cid:1)0.81(0.35) (cid:1)1.53(0.37) 0.72(0.47) Self-administeredMHGQoverallscore†[adjustedmean(SE)] Week24 2.8(0.75) 3.0(0.95) 2.9(0.89) Investigator-assessedchangeinpatienthairgrowth/loss‡[adjustedmean (SE)] Week24 0.8(0.09)* 0.3(0.09) 0.7(0.12) Blinded-assessorchangeinpatienthairgrowth/loss‡[adjustedmean (SE)] Week24 0.2(0.09) 0.1(0.09) 0.3(0.12)

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table4 Frequencyoftreatmentemergentadverseevents(TEAEs)inthesafetypopulation from Topicalfinasteride Placebo Oralfinasteride Total https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, (N=181) PatientswithTEAEs,n(%) 75(41.4) Mild 59(32.6) Moderate 32(17.7) Severe† 4(2.2) PatientswithTEAEsleadingtostudydiscontinuation,n(%) 5(2.8) Patientswithtreatment-relatedTEAEs‡,n(%) 18(9.9) Patientswithtreatment-relatedTEAEsleadingto 4(2.2) studydiscontinuation Patientswithtreatment-emergentseriousAEs 4(2.2) Patientswithtreatment-relatedseriousAEs 0 †Casesofunknownintensitywereassumedtobesevere. (N=181) (N=84) (N=446) 76(42.0) 41(48.8) 192(43.0) 60(33.1) 33(39.3) 152(34.1) 31(17.1) 19(22.6) 82(18.4) 3(1.7) 2(2.4) 9(2.0) 4(2.2) 6(7.1) 15(3.4) 12(6.6) 10(11.9) 40(9.0) 2(1.1) 2(2.4) 8(1.8) 5(2.8) 1(1.2) 10(2.2) 0 0 0 Wiley

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table4 Frequencyoftreatmentemergentadverseevents(TEAEs)inthesafetypopulation from Topicalfinasteride Placebo Oralfinasteride Total https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, (N=181) PatientswithTEAEs,n(%) 75(41.4) Mild 59(32.6) Moderate 32(17.7) Severe† 4(2.2) PatientswithTEAEsleadingtostudydiscontinuation,n(%) 5(2.8) Patientswithtreatment-relatedTEAEs‡,n(%) 18(9.9) Patientswithtreatment-relatedTEAEsleadingto 4(2.2) studydiscontinuation Patientswithtreatment-emergentseriousAEs 4(2.2) Patientswithtreatment-relatedseriousAEs 0 †Casesofunknownintensitywereassumedtobesevere. (N=181) (N=84) (N=446) 76(42.0) 41(48.8) 192(43.0) 60(33.1) 33(39.3) 152(34.1) 31(17.1) 19(22.6) 82(18.4) 3(1.7) 2(2.4) 9(2.0) 4(2.2) 6(7.1) 15(3.4) 12(6.6) 10(11.9) 40(9.0) 2(1.1) 2(2.4) 8(1.8) 5(2.8) 1(1.2) 10(2.2) 0 0 0 Wiley

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Treatment-related sexual adverse events (sexual dysfunction, Online erectile dysfunction, libido decreased, loss of libido) were Library reportedin2.8%vs.3.3%vs.4.8%ofpatientstreatedwithtopi-

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Treatment-related sexual adverse events (sexual dysfunction, Online erectile dysfunction, libido decreased, loss of libido) were Library reportedin2.8%vs.3.3%vs.4.8%ofpatientstreatedwithtopi-

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table4 Frequencyoftreatmentemergentadverseevents(TEAEs)inthesafetypopulation from Topicalfinasteride Placebo Oralfinasteride Total https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, (N=181) PatientswithTEAEs,n(%) 75(41.4) Mild 59(32.6) Moderate 32(17.7) Severe† 4(2.2) PatientswithTEAEsleadingtostudydiscontinuation,n(%) 5(2.8) Patientswithtreatment-relatedTEAEs‡,n(%) 18(9.9) Patientswithtreatment-relatedTEAEsleadingto 4(2.2) studydiscontinuation Patientswithtreatment-emergentseriousAEs 4(2.2) Patientswithtreatment-relatedseriousAEs 0 †Casesofunknownintensitywereassumedtobesevere. (N=181) (N=84) (N=446) 76(42.0) 41(48.8) 192(43.0) 60(33.1) 33(39.3) 152(34.1) 31(17.1) 19(22.6) 82(18.4) 3(1.7) 2(2.4) 9(2.0) 4(2.2) 6(7.1) 15(3.4) 12(6.6) 10(11.9) 40(9.0) 2(1.1) 2(2.4) 8(1.8) 5(2.8) 1(1.2) 10(2.2) 0 0 0 Wiley

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table4 Frequencyoftreatmentemergentadverseevents(TEAEs)inthesafetypopulation from Topicalfinasteride Placebo Oralfinasteride Total https://onlinelibrary.wiley.com/doi/10.1111/jdv.17738, (N=181) PatientswithTEAEs,n(%) 75(41.4) Mild 59(32.6) Moderate 32(17.7) Severe† 4(2.2) PatientswithTEAEsleadingtostudydiscontinuation,n(%) 5(2.8) Patientswithtreatment-relatedTEAEs‡,n(%) 18(9.9) Patientswithtreatment-relatedTEAEsleadingto 4(2.2) studydiscontinuation Patientswithtreatment-emergentseriousAEs 4(2.2) Patientswithtreatment-relatedseriousAEs 0 †Casesofunknownintensitywereassumedtobesevere. (N=181) (N=84) (N=446) 76(42.0) 41(48.8) 192(43.0) 60(33.1) 33(39.3) 152(34.1) 31(17.1) 19(22.6) 82(18.4) 3(1.7) 2(2.4) 9(2.0) 4(2.2) 6(7.1) 15(3.4) 12(6.6) 10(11.9) 40(9.0) 2(1.1) 2(2.4) 8(1.8) 5(2.8) 1(1.2) 10(2.2) 0 0 0 Wiley

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

group.Treatment-relatedTEAEsreportedby≥3patientsinany ofthetopicalfinasteride,placeboororalfinasteridegroupswere: pruritus (2.2% vs. 0.6% vs. 1.2% of patients, respectively),

Citation complémentaire (valeur)

erythema(2.2%,0%,and0%,respectively),andlossoforreduc- (https://onlinelibrary.wiley.com/terms-and-conditions) tioninlibido(0.6%,2.8%and4.8%,respectively).

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

group.Treatment-relatedTEAEsreportedby≥3patientsinany ofthetopicalfinasteride,placeboororalfinasteridegroupswere: pruritus (2.2% vs. 0.6% vs. 1.2% of patients, respectively),

Citation complémentaire (valeur)

erythema(2.2%,0%,and0%,respectively),andlossoforreduc- (https://onlinelibrary.wiley.com/terms-and-conditions) tioninlibido(0.6%,2.8%and4.8%,respectively).

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

group.Treatment-relatedTEAEsreportedby≥3patientsinany ofthetopicalfinasteride,placeboororalfinasteridegroupswere: pruritus (2.2% vs. 0.6% vs. 1.2% of patients, respectively),

Citation complémentaire (valeur)

erythema(2.2%,0%,and0%,respectively),andlossoforreduc- (https://onlinelibrary.wiley.com/terms-and-conditions) tioninlibido(0.6%,2.8%and4.8%,respectively).

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

group.Treatment-relatedTEAEsreportedby≥3patientsinany ofthetopicalfinasteride,placeboororalfinasteridegroupswere: pruritus (2.2% vs. 0.6% vs. 1.2% of patients, respectively),

Citation complémentaire (valeur)

erythema(2.2%,0%,and0%,respectively),andlossoforreduc- (https://onlinelibrary.wiley.com/terms-and-conditions) tioninlibido(0.6%,2.8%and4.8%,respectively).

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Incidences of treatment-related TEAEs were 9.9%, 6.6% and 11.9% in the topical finasteride, placebo and oral finasteride groups, respectively. Withdrawal rates due to treatment-related TEAEs were 2.8% and 2.2% in the topical finasteride and pla- cebo groups, respectively, and 7.1% in the topical finasteride group.Treatment-relatedTEAEsreportedby≥3patientsinany ofthetopicalfinasteride,placeboororalfinasteridegroupswere: pruritus (2.2% vs. 0.6% vs. 1.2% of patients, respectively),

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Incidences of treatment-related TEAEs were 9.9%, 6.6% and 11.9% in the topical finasteride, placebo and oral finasteride groups, respectively. Withdrawal rates due to treatment-related TEAEs were 2.8% and 2.2% in the topical finasteride and pla- cebo groups, respectively, and 7.1% in the topical finasteride group.Treatment-relatedTEAEsreportedby≥3patientsinany ofthetopicalfinasteride,placeboororalfinasteridegroupswere: pruritus (2.2% vs. 0.6% vs. 1.2% of patients, respectively),

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

MeanserumDHTconcentrationsatweek24were34.6%lower than at baseline in the topical finasteride group (25.75 vs. 39.32 ng/dL, respectively), and were 55.6% lower than at base- lineintheoralfinasteridegroup(15.75vs.35.50 ng/dL,respec- tively). The adjusted mean difference in the change from baseline in serum DHT concentrations was statistically signifi- cant between topical finasteride and placebo (P < 0.05), and < between topical finasteride and oral finasteride (P 0.05), at eachofweeks4,8,12and24(Fig. 5).

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

MeanserumDHTconcentrationsatweek24were34.6%lower than at baseline in the topical finasteride group (25.75 vs. 39.32 ng/dL, respectively), and were 55.6% lower than at base- lineintheoralfinasteridegroup(15.75vs.35.50 ng/dL,respec- tively). The adjusted mean difference in the change from baseline in serum DHT concentrations was statistically signifi- cant between topical finasteride and placebo (P < 0.05), and < between topical finasteride and oral finasteride (P 0.05), at eachofweeks4,8,12and24(Fig. 5).

Piraccini BM, Blume-Peytavi U, Scarci F et al.. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.. J Eur Acad Dermatol Venereol 2022, DOI 10.1111/jdv.17738. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).